Wyden Statement on Reports of Ways and Means Drug Pricing Markup

Senate Finance Committee Ranking Member Ron Wyden, D-Ore., today issued a statement after news reports indicated the House Ways & Means Committee will be marking up drug pricing legislation including Wyden-initiated bills that address price gouging and secrecy in the drug pricing system:

“I am pleased that the House is advancing my bills to bring accountability and transparency to Big Pharma and drug middlemen,” Wyden said. “I look forward to continuing my work with Chairman Grassley and other members of the Finance Committee on these and other ideas with the goal of delivering lower drug prices to American consumers.”

Wyden reintroduced the SPIKE Act and the C-THRU Act earlier this year. More information on the bills may be found here.

###

• Print
• Email
• Tweet